RxDoctor Payments DataLook up a doctor →

Harry Sarles, MD

Gastroenterology · Rockwall, TXNPI 1861451395

Payments from drug & device makers

$4,086,590in general payments, 2019–2025

Across 1,405 payments — averaging $2908.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1.4M
  • Regeneron$450K
  • Janssen Research & Development, LLC$421K
  • E.r. Squibb & Sons, L.L.C.$419K
  • Takeda Pharmaceuticals U.S.A., Inc.$272K
  • Gilead$264K
  • plus $852K from 46 others
$17,409in research payments, 2019–2025

Across 26 payments — averaging $669.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$14K
  • Regeneron$2K
  • AbbVie$909

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)500$1,408,668
Regeneron89$449,623
Janssen Research & Development, LLC65$421,469
E.r. Squibb & Sons, L.L.C.29$419,144
Takeda Pharmaceuticals U.S.A., Inc.129$271,582
Gilead70$264,263
Eli Lilly24$235,731
Pfizer(2 entities)61$138,983
Bristol Myers Squibb62$118,980
Ironwood Pharmaceuticals, Inc24$78,984
Phathom Pharmaceuticals, Inc.69$47,128
Adare Pharmaceuticals, Inc.20$41,524
Boehringer Ingelheim International GmbH26$34,831
Genentech, Inc.5$34,418
Astrazeneca UK Limited3$26,320
Teva Pharmaceuticals USA, Inc.4$23,800
Vanda Pharmaceuticals Inc.2$18,061
Bausch Health US, LLC2$16,500
F. Hoffmann-la Roche AG3$16,232
Redhill Biopharma Inc.9$8,956
Johnson & Johnson(2 entities)49$3,008
Regeneron Healthcare Solutions, Inc.10$2,879
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC21$2,523
Sanofi15$492
Ferring Pharmaceuticals Inc.14$272
Janssen Scientific Affairs, LLC4$266
Ardelyx, Inc.9$213
Vivus LLC13$193
Amgen7$174
Intercept Pharmaceuticals, Inc.9$172
Medtronic5$171
Merck7$123
Daiichi Sankyo Inc.7$113
Ipsen Biopharmaceuticals, Inc4$103
Boston Scientific1$99
Lilly USA, LLC3$80
Nestle Healthcare Nutrition Inc.4$76
Shield Therapeutics Inc1$73
Celltrion USA Inc.2$42
Alfasigma USA, Inc.2$41
Organon5$39
Braintree Laboratories, Inc.2$34
Boehringer Ingelheim2$33
QOL Medical, LLC2$32
Madrigal Pharmaceuticals1$25
Pacira Pharmaceuticals Incorporated1$24
UCB, Inc.1$22
Endogastric Solutions, Inc1$20
Abbott1$18
Novo Nordisk1$18
Shionogi Inc1$13
Gastrogpo, LLC4$0

How this compares

$4,086,590 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas →

Medicare billing

Part B allowed, 2024
$212,745
Medicare patients
512
Services billed
5,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Rockwall

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →